Business
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
Robert Dempsey Robert Dempsey, CEO of OKYO Pharma Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condit
About this update from Okyo Pharma Limited
[{"type":"image","alt":"OKYO Pharma LTD","displaySize":"","headline":null,"caption":"OKYO Pharma LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5rBQz17s3GxW5mY3tWfBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f","width":300,"height":113}},"lazy":false},{"type":"text","content":"Robert Dempsey","length":14,"tagName":"p"},{"type":"image","alt":"Robert Dempsey, CEO of OKYO Pharma","displaySize":"","headline":null,"caption":"Robert Dempsey, CEO of OKYO Pharma","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":2898,"height":2320,"url":"https://media.zenfs.com/en/globenewswire.com/19381360b0d29b0fd89b3cedfea08c9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iZCLjjjP6T7XMIQoabsjWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/19381360b0d29b0fd89b3cedfea08c9d","width":960,"height":769},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/cNTz6P8XJS8KbBeM1AdJRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xOTIyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/19381360b0d29b0fd89b3cedfea08c9d","width":1200,"height":961}}},{"type":"list","items":[{"val":[{"type":"text","content":"Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise ","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":207,"olType":false},{"type":"text","content":"LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and continue to serve as a member of the Boa...